|
gptkbp:instanceOf
|
gptkb:chemical_compound
neurosteroid
|
|
gptkbp:actsOn
|
gptkb:GABAA_receptor
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedDrugFor
|
postpartum depression
|
|
gptkbp:CASNumber
|
516-54-1
|
|
gptkbp:chemicalFormula
|
C21H34O2
|
|
gptkbp:derivedFrom
|
gptkb:progesterone
|
|
gptkbp:drugClass
|
benzodiazepine
sedative
anticonvulsant
antidepressant
positive allosteric modulator
|
|
gptkbp:eliminationHalfLife
|
9 hours
|
|
gptkbp:foundIn
|
gptkb:human
gptkb:adrenal_gland
gptkb:placenta
ovaries
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
allopregnanolone
|
|
gptkbp:isomerOf
|
gptkb:pregnanolone
isopregnanolone
|
|
gptkbp:IUPACName
|
(3α,5α)-3-hydroxy-5-pregnan-20-one
|
|
gptkbp:marketedAs
|
gptkb:brexanolone
|
|
gptkbp:meltingPoint
|
163–166 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
318.49 g/mol
|
|
gptkbp:predecessor
|
gptkb:pregnanolone
|
|
gptkbp:PubChem_CID
|
9270
CHEBI:16827
|
|
gptkbp:sideEffect
|
gptkb:hypoxia
nausea
vomiting
diarrhea
anxiety
dizziness
fatigue
headache
loss of consciousness
insomnia
sedation
tachycardia
euphoria
dry mouth
dyspepsia
flushing
somnolence
decreased appetite
dysgeusia
hyperhidrosis
hot flush
dizziness postural
|
|
gptkbp:UNII
|
19YFY9D77K
|
|
gptkbp:bfsParent
|
gptkb:brexanolone
|
|
gptkbp:bfsLayer
|
7
|